Author: Vanessa Ngan, Staff Writer, 2004.

Pimecrolimus is a topical steroid-free medication with immune-modulating and anti-inflammatory properties. It is classified as a calcineurin inhibitor. It is an ascomycin macrolactam derivative (ascomycin is produced by Streptomyces hygroscopicus). Pimecrolimus is available in New Zealand as a 1% strength cream in a 15g tube. The trade name is Elidel®.

How does pimecrolimus work?

Although the mechanism of action of pimecrolimus in the treatment of atopic dermatitis is not yet completely understood, the following immune-modulating effects have been noticed.

What is pimecrolimus used for?

Pimecrolimus is approved for use for the short-term and intermittent long-term treatment of atopic dermatitis in patients that are over 3 months of age. In some countries, it is only approved for use in the over 2's.

There is no cure for atopic dermatitis, but pimecrolimus provides a steroid-free alternative treatment for controlling the symptoms. It relieves the itch and inflammation caused by atopic dermatitis.

Pimecrolimus cream may prove useful for many other skin conditions that respond to topical steroids (such as other types of eczema/dermatitis) but there is very little published data to confirm this. Dermatologists are likely to recommend pimecrolimus cream in other diseases when there is poor response to conventional treatments or side effects have arisen.

How to use pimecrolimus cream

Pimecrolimus cream (Elidel®) is a prescription medicine and should be used only as directed by your doctor. Pimecrolimus cream may be applied to all skin surfaces including the head, face, neck, around the eyes, and skin folds.

Pimecrolimus should be used as follows:

Pimecrolimus cream is odour free, non-greasy and absorbs quickly into the skin so that it shouldn't stain clothes or bedding.

Precautions if you are using pimecrolimus cream

Side effects of pimecrolimus cream

Most patients tolerate pimecrolimus cream well. Initial research indicates it can be used on large areas of the body and for long periods of time without adverse effects, due to low level of absorption internally. However there is no published data in its use for more than one year.

The most common side effect that can be experienced around the site of application is a feeling of warmth or a sensation of burning. This is usually mild to moderate in severity and goes away within a few days after starting treatment. However, if this reaction persists for more than one week you should see your doctor. There appears to be a slightly increased susceptibility to skin infections such as folliculitis, impetigo, herpes simplex and molluscum contagiosum.

Other less common reported adverse reactions during research trials include headache, cough, fever, coldlike symptoms but these were no more likely in patients receiving pimecrolimus than those using a control placebo cream.

Most data published regarding the tolerability of pimecrolimus comes from studies in adult patients. However, limited studies to date concerning infants and children using the cream for up to a year have shown that pimecrolimus appears to be well tolerated in all age groups. The risk for systemic side effects and skin atrophy, problems commonly associated with the use of topical corticosteroids, has not been found with pimecrolimus use. However, as this is a new drug, the full safety profile of the medication is unknown; the main concerns relate to its effect on the immune system. The risk of skin cancer and lymphoma appears to be very low but is being carefully monitored at this time (May 2005).

Pimecrolimus has not been tested in pregnant women but studies have indicated that it is unlikely to have harmful effects on the fetus. It is not known whether it is excreted in breast milk but it is not thought to pose any risk to a baby. Nevertheless, because there isn't much information about this new medication, it is safest to avoid using it when pregnant or breastfeeding.

New Zealand approved datasheets are the official source of information for these prescription medicines, including approved uses and risk information. Check the individual New Zealand datasheet on the Medsafe website.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter